- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05979363
Une étude sur le bortézomib, le lénalidomide et la dexaméthasone (VRd) suivis d'une thérapie BCMA CAR-T chez des patients non éligibles à la greffe atteints de leucémie primaire à plasmocytes (CAREMM-002)
Safety and Efficiency of VRd-based Regimen Combining BCMA CAR-T for Transplant-ineligible Patients With Primary Plasma Cell Leukemia: a Prospective, Single-arm, Single-center, Phase II Study.
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study is a prospective, single-arm, single-centre, phase II study designed to evaluate the efficacy and safety of treatment with VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia. Patients received 3-4 courses of induction therapy with VRD-based regimen followed by infusion of BCMA CAR-T cells. Patients then received 2-3 courses of consolidation therapy, followed by maintenance therapy.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gang An, PhD&MD
- Numéro de téléphone: 86-022-23909171
- E-mail: angang@ihcams.ac.cn
Lieux d'étude
-
-
-
Tianjin, Chine
- Recrutement
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
-
Contact:
- Gang An, PhD&MD
- Numéro de téléphone: 008613502181109
- E-mail: angang@ihcams.ac.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years and ≤ 75 years.
- Participants with documented primary plasma cell leukemia according to IMWG diagnostic criteria (circulating plasma cells ≥5%, determined by morphology on peripheral blood smear; or absolute value of peripheral blood tumorigenic plasma cells exceeds 2×10^9/L).
- Measurable disease, at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain MM without measurable disease in serum or urine: serum Ig free-light chain (FLC) ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
- Not considered for high-dose chemotherapy with Autologous Stem Cell Transplant (ASCT) due to: Ineligible due to advanced age (≥65); or Ineligible evaluated by researchers; or Eastern Cooperative Oncology Group Performance Status grade of 3 or 4; or Repeated hematopoietic stem cell mobilization failure; or Deferral of high-dose chemotherapy with ASCT as initial treatment.
- Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
- All screening blood biochemistry: tests should be performed according to the protocol and within 14 days before enrollment. Screening laboratory values must meet the following criteria: a.TBIL<2 x upper limit of normal (ULN) (<3 x ULN in patients with Gilbert's syndrome); b.AST and ALT <3 x ULN.; c. Creatinine clearance ≥ 30mL/min (calculated using Cockroft-Gault formula).
- Routine blood tests (performed within 7 days, no RBC transfusion, no G-CSF/GM-CSF/platelet agonists, no drug correction within 14 days before screening, no PLT transfusion within 7 days) : WBC ≥ 1.5 x 109/L, ANC ≥ 1.0 x 109/L, Hb ≥ 70 g/L PLT ≥ 75 x 109/L (if BMPC < 50%) or PLT ≥ 50 x 109/L (if BMPC ≥ 50%).
- Patients must be able to take prophylactic anticoagulant therapy as recommended by the study.
- The woman is not breastfeeding, is not pregnant and agrees not to be pregnant during the study period and for the following 12 months. Male patients agreed that their spouse would not become pregnant during the study period and for 12 months thereafter.
Exclusion Criteria:
- Documented active amyloidosis.
- Documented with central nervous system (CNS) invasion.
- Prior exposure to any BCMA-targeted therapy or CAR-T therapy.
- Patients with peripheral neuropathy greater than grade 2 or peripheral neuropathy greater than grade 2 with pain at baseline, regardless of whether they were currently receiving medical therapy.
- Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide, and BCMA-CART cellular products.
- Seropositive for human immunodeficiency virus (HIV)
- Hepatitis B infection
- Hepatitis C infection
- Life expectancy of <6 months
- Women who are pregnant or breastfeeding
- Any active gastrointestinal dysfunction that affects the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that may affect the absorption of the studied treatment medication
- Subjects had major surgery within 2 weeks before randomization (for example, general anesthesia), or is not fully recovered from the surgery, or surgery is arranged during study period.
- Received live attenuated vaccine within 4 weeks prior to study treatment.
- According to the researcher's judgment, any condition including but not limited to serious mental illness, medical illness, or other symptoms/conditions that may affect study treatment, compliance, or the capability of providing informed consent.
- Necessary medication or supportive therapy is contraindicated with study treatment.
- Any diseases or complications that may interfere with the study.
- Patients are not willing to or cannot comply with study scheme.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: VRD-based Regimen Combined With BCMA CART
VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22 in a 28-day cycle. BCMA CAR-T products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Participants will receive VRD-based induction, BCMA CAR-T infusion, consolidation, and maintenance. |
Patients receive a single intravenous infusion of one of two BCMA-directed autologous CAR T-cell products: YK-BB-002: Target dose of 3.0 × 10⁶ CAR-positive T cells/kg; Equecabtagene autoleucel: Planned dose of 1.0 × 10⁶ CAR-positive T cells/kg. Bortezomib, Lenalidomide and Dexamethasone |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and Tolerability
Délai: Up to 2 year
|
The incidence of treatment-emergent adverse events (TEAEs) |
Up to 2 year
|
|
MRD-negative rate
Délai: within 1 week after consolidation treatment
|
achieving MRD-negative, as determined by NGF after consolidation treatment |
within 1 week after consolidation treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Complete response rate (CRR)
Délai: within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
|
CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria |
within 1 week after induction therapy, 1 month after the CAR-T cell transfusion, within 1 week after consolidation therapy
|
|
Progression free survival (PFS)
Délai: Up to 2 year
|
Progression free survival is defined as the time from the date of enrollment to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first |
Up to 2 year
|
|
Overall Survival (OS)
Délai: Up to 5 year
|
Overall survival is measured from the date of enrollment to the date of the participant's death. |
Up to 5 year
|
|
Duration of Remission(DOR)
Délai: Up to 2 year
|
Duration of response is defined as the time from the first documented partial response (PR) or better to disease progression or death from any cause, whichever occurs first. |
Up to 2 year
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The duration of CART cell in vivo
Délai: Up to 1 year
|
The copies of BCMA-CART DNA in peripheral blood with qPCR method |
Up to 1 year
|
|
Change from Baseline in Physical status assessed by International Myeloma Working Group Comprehensive Geriatric Assessment (IMWG-CGA) scores
Délai: Baseline up to 5 years
|
The IMWG-CGA was calculated by combining age, activities of daily living (ADL), instrumental ADL (IADL), and Charlson Comorbidity Index (CCI), which ranges from 0 to 5 with higher scores indicating worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by activities of daily living (ADL) scores
Délai: Baseline up to 5 years
|
The ADL includes 4 items (transfer, bed mobility, toileting, and eating), which range from 0 to 6 scores. A higher score represents worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by instrumental activities of daily living (IADL) scores
Délai: Baseline up to 5 years
|
The IADL includes 5 items (cooking, cleaning, transportation, laundry, and managing finances), which range from 0 to 8 scores. A higher score represents worse physical condition and greater weakness. |
Baseline up to 5 years
|
|
Change from Baseline in Physical status assessed by Charlson Comorbidity Index (CCI)
Délai: Baseline up to 5 years
|
The CCI estimates the number and the severity of comorbidities, including nineteen diseases with a score varying from 1 to 6 for each of them in accordance to their severity. The score can range from 0 to 37. A higher score represents more severe comorbidities. |
Baseline up to 5 years
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IIT2023034
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .